CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Winlevi (clascoterone) 1% & Adapalene 0.3% geldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06336603
NCT06336603Phase 4Completed
CompareCT.gov

The Combination Use of Winlevi and Adapalene 0.3% Gel in Real Life Acne Treatment

Sun Pharmaceutical Industries Limited·interventional·Posted Mar 29, 2024·Updated Oct 9, 2025

In Brief

A Phase 4 clinical trial evaluating Winlevi (clascoterone) 1% & Adapalene 0.3% gel for Acne Vulgaris. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris. There is no study assessing Winlevi in combination treatment for acne .Therefore this study assesses Winlevi with Adapalene 0.3% gel in combination to emulate real life practice.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202420252026
First PostedMar 29, 2024
Enrollment StartNov 15, 2023
Primary CompletionOct 29, 2024
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 2.3 years ago

Interventions

Winlevi (clascoterone) 1% & Adapalene 0.3% geldrug

Participants will use Winlevi (clascoterone) 1% twice daily (BID) and Adapalene 0.3% once daily (QD)